World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Who’s Going to World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

165 organizations and 171 speakers at World ADC San Diego 2026, a ~1,300-person, almost entirely industry meeting of antibody-drug conjugate developers. As of Oct 8, 2026.

Format
Stream
Top represented
Showing 1–7 of 165 organizations
OrganizationWorld ADC San Diego 2026 Attendance
Merck & Co.
Rahway, NJ
Large pharma
Global pharmaceutical company, known as MSD outside the US and Canada, with marketed cancer medicines and an ADC pipeline.
Panel
Mon Oct 12
12:00pm
Breaking Down Strategic Approaches to Ensure Product Quality in Late-Stage ADC Manufacturing
Pre-conference: 8th CMC Day
Talk
Wed Oct 14
11:00am
Harnessing Computational & Mechanistic Insights Into Chemoselective Reduction for Engineered Cysteine Site-Specific ADCs
Discovery Chemistry
Talk
Wed Oct 14
12:00pm
Talk
Wed Oct 14
2:00pm
Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design
Translational Medicine
Talk
Wed Oct 14
3:00pm
Evaluating Environmental Temperature as a Hidden Critical Factor in icIEF for a Late-Stage ADC
Process & Analytical Development
Daiichi Sankyo
Tokyo, Japan
Large pharma
Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.
Panel
Mon Oct 12
2:30pm
Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION
Pre-conference: 7th Toxicity Day
Panel
Tue Oct 13
8:00am
Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more
ADC discovery chemistryADC discovery biology
Panel
Tue Oct 13
3:30pm
Talk
Wed Oct 14
2:00pm
Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1
Preclinical
Workshop
Thu Oct 15
1:00pm
Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape
Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio
Pfizer
New York, NY
Large pharma
Global pharmaceutical company whose oncology portfolio includes ADCs gained with Seagen, such as PADCEV.
Panel
Tue Oct 13
8:00am
Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more
ADC discovery chemistryADC discovery biology
Talk
Tue Oct 13
12:00pm
Talk
Tue Oct 13
2:00pm
Panel
Tue Oct 13
3:30pm
What’s the New Path to the Next Generation of ADCs?
Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more
Chair
Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance
Discovery Chemistry
Panel
Wed Oct 14
2:30pm
What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation?
Discovery Chemistry
AstraZeneca
Cambridge, UK
Large pharma
Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo.
Chair
Unlocking the Therapeutic Power of Rationale-Driven ADC Combinations
Pre-conference: 10th ADCs in Combination Day
Talk
Mon Oct 12
10:00am
Combining the Past, Present & Future: Learnings, Trends & Impact of the Past 10 Years of ADC Combination Therapies
Pre-conference: 10th ADCs in Combination Day
Talk
Tue Oct 13
11:00am
Evaluating CMC Projects to Ensure Sustainable, Time & Cost Sensitive Manufacturing Across the ADC Product Portfolio
Manufacturing & Supply Chain
Talk
Tue Oct 13
11:00am
Panel
Tue Oct 13
3:30pm
What’s the New Path to the Next Generation of ADCs?
Discovery Biology · with Sygnature Discovery, Iksuda Therapeutics, Pfizer +1 more
Biotech
Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.
Talk
Tue Oct 13
12:00pm
Talk
Tue Oct 13
2:00pm
Panel
Tue Oct 13
3:30pm
What’s the New Path to the Next Generation of ADCs?
Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more
Panel
Tue Oct 13
5:45pm
Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners?
Plenary · with Exelixis, Genentech, Veranova +1 more
ADC discovery chemistryManufacturing & supply chain
Chair
Exelixis
Alameda, CA
Biotech
Oncology company with marketed cabozantinib and a pipeline of biotherapeutics, including masked ADCs.
Chair
Manufacturing Cost Efficient & Regulatory Compliant ADCs at Scale
Pre-conference: 8th CMC Day
Panel
Mon Oct 12
10:30am
Discussing Best Practices & Opportunities With Existing ADC Regulatory CMC Legislation & Data Submissions
Pre-conference: 8th CMC Day
Talk
Mon Oct 12
10:30am
Evaluating Design & Preclinical Characterization of XB404, a Masked ADC Targeting ROR1 & ROR2
Pre-conference: 3rd Pharmacology Day
Talk
Tue Oct 13
2:00pm
Navigating Platform Process Development Approaches to Ensure mAb Readiness for Diverse Conjugation Approaches
Process & Analytical Development
Panel
Tue Oct 13
5:45pm
Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners?
Plenary · with Genentech, Callio Therapeutics, Veranova +1 more
ADC discovery chemistryManufacturing & supply chain
Talk
Wed Oct 14
12:00pm
Regeneron
Tarrytown, NY
Large pharma
Develops and markets antibody medicines, and researches new linker-payloads and bioconjugate designs beyond classic cytotoxic ADCs.
Chair
Pushing the Boundary of Novel Bioconjugate Mechanisms & Design
Pre-conference: 4th Novel Conjugates Day
Talk
Mon Oct 12
12:00pm
Spotlighting Discovery of Novel Linker Payloads to Set the Path for the Next Wave of Differentiated Antibody Conjugates
Pre-conference: 4th Novel Conjugates Day
Panel
Mon Oct 12
3:00pm
Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation
Pre-conference: 4th Novel Conjugates Day
Panel
Tue Oct 13
8:00am
Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more
ADC discovery chemistryADC discovery biology
Talk
Wed Oct 14
12:00pm
The 18-Month Journey to Clinic for ADCs: How Operational Strategy Sets The Pace for IND
Manufacturing & Supply Chain
Workshop
Thu Oct 15
1:00pm
Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities
Post-conference workshop for Process & Analytical Development · with Bristol Myers Squibb, Gilead Sciences

Explore the full World ADC San Diego 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Diego. Leave your work email and we’ll be in touch.

Privacy

Download the full World ADC San Diego 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from companies at World ADC San Diego 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

When and where was World ADC San Diego 2026?

17th World ADC San Diego ran October 12–15, 2026, at Town & Country San Diego in San Diego, CA.

What conference is this?

World ADC San Diego is an annual antibody–drug conjugate meeting, held October 12–15, 2026 at the Town & Country San Diego. It brings together ADC discovery, preclinical, translational, clinical, process and manufacturing teams from pharma and biotech with the CDMOs, CROs and suppliers that serve them, across seven content streams, a pre-conference seminar day and a post-conference workshop day.

What is in this guide?

Every organization we can place at World ADC San Diego 2026: 171 speakers from the public agenda (198 talks, panels, chaired sessions, workshops and hosted sessions) rolled up to their companies and institutions, and the 101 partners from the public partner list with their tier, 39 of them Exhibition Partners — 165 organizations in one list. Speakers appear as job titles, never by name. The organizers publish no attendee list and no booth numbers.

How are organizations typed?

By the role an organization plays in ADC development: drug developers (large pharma and biotech), then the companies around them — CDMOs and CROs, instrument and equipment makers, reagent, material and model-system suppliers, software and data companies, and consultancies and other services — and academic, government and non-profit bodies. The stream filters come from the content stream, seminar or workshop a session sits in.

How current is it?

Pulled from the public speaker faculty, the day-by-day agenda and the partner list on October 8, 2026, four days before the meeting opens. The organizers add and move sessions up to the meeting itself.

Browse World ADC San Diego 2026 by

Organizations with their own page

130 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by World ADC or its organizers. Submit a correction